Key result
Transcatheter tricuspid valve intervention is at an early stage of development, and its potential role in high-risk patients with severe tricuspid regurgitation needs to be determined.
Transcatheter tricuspid valve interventions are emerging as a potential treatment option for high-risk patients with severe tricuspid regurgitation, guided by principles from current surgical guidelines.
Tricuspid regurgitation (TR) is an important clinical problem because it is frequent and carries a poor prognosis when it is left uncorrected. However, there is still a lack of awareness of tricuspid disease in the medical community. The indications for evaluation and surgical interventions in patients with TR were recently updated in the ESC/EACTS guidelines. Transcatheter tricuspid valve intervention (TTVI), almost exclusively valve repair, is at an early stage of development as only a few hundreds of patients have been treated. The first-in-man valve implantation was very recently performed. The recent ESC/EACTS Guidelines state that "The potential role of transcatheter tricuspid valve treatment in high-risk patients needs to be determined". We shall review here which lessons of interest for TTVI can be learned from the Guidelines as regards evaluation and indications for surgery and try to imagine what could be the place of TTVI in the Guidelines in the future.
No takes yet. Share an insight, caveat, or question.
Vahanian et al. (2018) conducted a review in Tricuspid regurgitation. Transcatheter tricuspid valve intervention (TTVI) was evaluated. Transcatheter tricuspid valve intervention is at an early stage of development, and its potential role in high-risk patients with severe tricuspid regurgitation needs to be determined.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: